Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal CarcinomaYuan Zhang, Jun Ma, Jing Huang et al.|New England Journal of Medicine|2019Cited by 934
Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinomaYu‐Pei Chen, Jun Ma, Jianhua Yin et al.|Cell Research|2020Cited by 483
Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma: CSCO and ASCO GuidelineYu‐Pei Chen, Nofisat Ismaila, Melvin L.K. Chua et al.|Journal of Clinical Oncology|2021Cited by 393
Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: a multicentre, open-label, parallel-group, randomised, controlled, phase 3 trialYu‐Pei Chen, Jun Ma, Xu Liu et al.|The Lancet|2021Cited by 234
Liquid biopsy tracking during sequential chemo-radiotherapy identifies distinct prognostic phenotypes in nasopharyngeal carcinomaJia‐Wei Lv, Ying Sun, Yu‐Pei Chen et al.|Nature Communications|2019Cited by 163